Lifeward (LFWD) Aktienübersicht
Lifeward Ltd. ist ein Medizintechnikunternehmen, das Technologien entwickelt und vertreibt, die Mobilität und Wohlbefinden in der Rehabilitation und im täglichen Leben für Menschen mit körperlichen und neurologischen Erkrankungen in den Vereinigten Staaten, Europa, Deutschland, im asiatisch-pazifischen Raum und international ermöglichen. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 3/6 |
| Künftiges Wachstum | 2/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 3/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
LFWD Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Lifeward Ltd. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$6.78 |
| 52-Wochen-Hoch | US$13.80 |
| 52-Wochen-Tief | US$4.14 |
| Beta | 0.37 |
| 1 Monat Veränderung | 1.19% |
| 3 Monate Veränderung | -8.25% |
| 1 Jahr Veränderung | -48.64% |
| 3 Jahre Veränderung | -86.65% |
| 5 Jahre Veränderung | -95.41% |
| Veränderung seit IPO | -99.90% |
Aktuelle Nachrichten und Updates
LFWD: Higher Expected Revenue And Future P/E Multiple Will Support Upside
Analysts have raised their price target for Lifeward to $10 from $4.50, citing updated assumptions on revenue growth, profit margins, discount rate, and future P/E that support a higher valuation framework. What's in the News On May 15, 2026, Lifeward said it will not be able to file its next 10-Q by the SEC deadline, indicating a delay in its upcoming quarterly report.LFWD: Lower Discount Rate And Higher P/E Assumptions Support Upside Potential
Analysts have lifted their price target on Lifeward to $10 from $4.50, citing updated assumptions around discount rates, long term profit margins, and future P/E levels that feed into their fair value framework. Analyst Commentary Analysts revising their fair value frameworks for Lifeward point to changes in discount rates, long term margin assumptions, and targeted P/E levels as key drivers behind the new US$10 price target.Recent updates
LFWD: Higher Expected Revenue And Future P/E Multiple Will Support Upside
Analysts have raised their price target for Lifeward to $10 from $4.50, citing updated assumptions on revenue growth, profit margins, discount rate, and future P/E that support a higher valuation framework. What's in the News On May 15, 2026, Lifeward said it will not be able to file its next 10-Q by the SEC deadline, indicating a delay in its upcoming quarterly report.LFWD: Lower Discount Rate And Higher P/E Assumptions Support Upside Potential
Analysts have lifted their price target on Lifeward to $10 from $4.50, citing updated assumptions around discount rates, long term profit margins, and future P/E levels that feed into their fair value framework. Analyst Commentary Analysts revising their fair value frameworks for Lifeward point to changes in discount rates, long term margin assumptions, and targeted P/E levels as key drivers behind the new US$10 price target.
LFWD: Higher Fair Value Assumptions Will Shape Future P E Repricing
Analysts have raised their price target on Lifeward to $10 from $4.50, citing updated assumptions related to fair value, discount rate, revenue growth, profit margin and future P/E estimates. Analyst Commentary Bearish analysts describe the move to a US$10 price target as a recalibration rather than a clear vote of confidence, pointing out that the new target still reflects uncertainty around how Lifeward can deliver on the assumptions used in updated fair value work.
LFWD: Higher Risk Reward View Will Support Future Upside Potential
Analysts have raised their price target on Lifeward to $10 from $4.50, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple that together change their view of the company’s balance of risk and reward. Analyst Commentary Bullish analysts are framing the new US$10 price target as a reassessment of Lifeward’s potential risk and reward, rather than just a reaction to short term news.LFWD: Higher Fair Value Assumptions Will Support Future Cash Flow
Analysts have lifted the price target for Lifeward to $10 from $4.50, citing updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Analysts lifting the Lifeward price target to $10 from $4.50 are updating their view of what they see as fair value, based on refreshed assumptions for revenue growth, profitability, discount rates, and future P/E levels.LFWD: Reverse Split And Convertible Notes Will Support Future Upside
Analysts have raised their price target on Lifeward from $10.00 to about $120.00, citing updated views on revenue growth, profit margins, and a lower assumed future P/E multiple. What's in the News Lifeward plans dedicated clinic days with Shirley Ryan AbilityLab in Chicago starting in the second quarter of 2026, focused on evaluation and access to the FDA cleared ReWalk Personal Exoskeleton for people with spinal cord injury (Key Developments).LFWD: Reverse Split And New Financing Will Support Future Cash Flow
Analysts have lifted their price target for Lifeward to $87.00, supported by updated assumptions around fair value, discount rate, revenue growth, profit margin, and a lower future P/E multiple. What's in the News Lifeward plans a 1 for 12 reverse split of its ordinary shares, effective at the open of trading on February 24, 2026.LFWD: Convertible Notes And Share Actions Will Drive Future P E Repricing
Analysts have modestly adjusted their price target on Lifeward, citing updated assumptions around discount rate, revenue growth, profit margin, and future P/E that slightly refine their view of the company’s risk and earnings power in dollar terms. What's in the News Lifeward plans a Special and Extraordinary Shareholders Meeting on March 12, 2026 at its Hudson, Massachusetts offices to address corporate matters previously approved in principle at earlier meetings (company event filing).LFWD: New Convertible Funding And Reverse Split Will Support Future Upside
Narrative Update on Lifeward Analysts have slightly reduced their price target for Lifeward, citing small adjustments to the discount rate and future P/E assumptions, along with modest changes to expected revenue growth and profit margins. What's in the News Lifeward completed a private placement on November 14, 2025, issuing secured convertible promissory notes with an aggregate principal of $3,000,000, carrying 15% annual interest and convertible into ordinary shares at $0.45 per share, with participation from Oramed Ltd and maturity on May 14, 2026 (Key Developments).LFWD: Future P/E Repricing Will Rely On Successful Convertible Note Execution
Analysts have raised their price target for Lifeward to reflect higher modelled revenue growth of about 53% and a very large future P/E multiple, even as they factor in a lower profit margin and a slightly higher discount rate. What's in the News Lifeward entered into a private placement agreement to issue Senior Secured Convertible Notes with a principal amount of $20,000,000 and accompanying warrants, with the notes initially convertible at $0.45 per share and accruing 8.0% annual interest that may rise to 15.0% in the event of default (Key Developments).LFWD: Reverse Split And New Funding Will Set Up Future Upside
Analysts have reduced their fair value estimate for Lifeward from US$13.00 to US$10.00. They attribute this change to more conservative assumptions on revenue growth, profit margins and the P/E multiple they apply to the company.LFWD: Improved Capital Structure Will Support Future Cash Flow Potential
Analysts have nudged their price target for Lifeward slightly higher to reflect marginally lower perceived risk and modest improvements in long term profitability and valuation assumptions, even as their underlying fair value estimate remains anchored around $5.17 per share. What's in the News Lifeward completed a $3 million private placement via secured convertible promissory notes bearing 15% interest, convertible at $0.45 per share and maturing May 14, 2026, with participation from Oramed Ltd.LFWD: Improved Medicare Reimbursement Trends Will Support Future Cash Flow
Narrative Update on Lifeward The analyst price target for Lifeward has been revised upward to approximately 5.17 dollars per share from 5.17 dollars previously. This reflects analysts' expectations for faster revenue growth, improved profit margins, and a lower future price to earnings multiple.LFWD: Rising Medicare Approvals And New Funding Will Support Revenue Outlook
Analysts have significantly lowered their price target for Lifeward from $8.00 to approximately $5.17. They cite more conservative revenue growth projections and a notable reduction in expected profit margins.Even With A 27% Surge, Cautious Investors Are Not Rewarding Lifeward Ltd.'s (NASDAQ:LFWD) Performance Completely
Despite an already strong run, Lifeward Ltd. ( NASDAQ:LFWD ) shares have been powering on, with a gain of 27% in the...FDA Clearance And Expanded Payer Channels Will Drive Advanced Mobility
The consensus price target for Lifeward has been revised down to $8.00, primarily reflecting a sharp decrease in its future P/E multiple, while profitability remains stable. What's in the News Lifeward reset full-year 2025 earnings guidance under new management, targeting revenue of $24–$26 million.Many Still Looking Away From Lifeward Ltd. (NASDAQ:LFWD)
With a price-to-sales (or "P/S") ratio of 0.5x Lifeward Ltd. ( NASDAQ:LFWD ) may be sending very bullish signals at the...AlterG NEO And ReWalk 70 Will Shape Future Market Opportunities
Established lump sum payments and expanded into U.S. workers' compensation, creating stable revenue streams and improving net margins through efficient claim processing.Market Cool On Lifeward Ltd.'s (NASDAQ:LFWD) Revenues Pushing Shares 50% Lower
Lifeward Ltd. ( NASDAQ:LFWD ) shareholders won't be pleased to see that the share price has had a very rough month...Not Many Are Piling Into Lifeward Ltd. (NASDAQ:LFWD) Stock Yet As It Plummets 25%
Unfortunately for some shareholders, the Lifeward Ltd. ( NASDAQ:LFWD ) share price has dived 25% in the last thirty...Here's Why Lifeward (NASDAQ:LFWD) Must Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...ReWalk Robotics Ltd. (NASDAQ:LFWD) Soars 26% But It's A Story Of Risk Vs Reward
ReWalk Robotics Ltd. ( NASDAQ:LFWD ) shareholders are no doubt pleased to see that the share price has bounced 26% in...Is ReWalk Robotics (NASDAQ:LFWD) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Investors Give ReWalk Robotics Ltd. (NASDAQ:LFWD) Shares A 28% Hiding
ReWalk Robotics Ltd. ( NASDAQ:LFWD ) shares have had a horrible month, losing 28% after a relatively good period...Aktionärsrenditen
| LFWD | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | -3.2% | -0.5% | 0.9% |
| 1Y | -48.6% | -20.1% | 24.5% |
Rendite im Vergleich zur Industrie: LFWD unter dem Niveau der Branche US Medical Equipment , die im vergangenen Jahr eine Rendite von -20.1% erzielte.
Rendite vs. Markt: LFWD hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 24.5 erzielte.
Preisvolatilität
| LFWD volatility | |
|---|---|
| LFWD Average Weekly Movement | 8.3% |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: LFWD hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: LFWDDie wöchentliche Volatilität (8%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2001 | 81 | William Grant | golifeward.com |
Lifeward Ltd., ein Medizintechnikunternehmen, entwirft, entwickelt und vermarktet Technologien, die Mobilität und Wohlbefinden in der Rehabilitation und im täglichen Leben für Menschen mit körperlichen und neurologischen Erkrankungen in den Vereinigten Staaten, Europa, Deutschland, im asiatisch-pazifischen Raum und international ermöglichen. Das Unternehmen bietet ReWalk, ein persönliches Exoskelett und Exoskelett-Rehabilitationsgeräte für Menschen mit Rückenmarksverletzungen; ReStore Exo-Suit, ein weicher Exo-Anzug für die Rehabilitation von Menschen mit Behinderungen der unteren Gliedmaßen aufgrund eines Schlaganfalls; AlterG Anti-Gravity System für den Einsatz in der physischen und neurologischen Rehabilitation und im Sporttraining; MyoCycle-Geräte; und ReBoot, ein persönlicher weicher Exo-Anzug für die Verwendung zu Hause und in der Gemeinde für Menschen nach einem Schlaganfall. Das Unternehmen vermarktet und verkauft seine Produkte direkt an Einrichtungen und Einzelpersonen sowie über Drittvertriebshändler.
Lifeward Ltd.'s Grundlagenzusammenfassung
| LFWD grundlegende Statistiken | |
|---|---|
| Marktanteil | US$19.08m |
| Gewinn(TTM) | -US$25.87m |
| Umsatz(TTM) | US$20.92m |
Ist LFWD zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| LFWD Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$20.92m |
| Kosten der Einnahmen | US$13.28m |
| Bruttogewinn | US$7.65m |
| Sonstige Ausgaben | US$33.52m |
| Gewinn | -US$25.87m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -9.19 |
| Bruttomarge | 36.55% |
| Nettogewinnspanne | -123.66% |
| Schulden/Eigenkapital-Verhältnis | 115.7% |
Wie hat sich LFWD auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/06/14 11:48 |
| Aktienkurs zum Tagesende | 2026/06/12 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Lifeward Ltd. wird von 7 Analysten beobachtet. 2 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Matthew Taylor | Barclays |
| William Plovanic | Canaccord Genuity |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |